{"id":"NCT00481247","sponsor":"Bristol-Myers Squibb","briefTitle":"A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia","officialTitle":"An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2009-12","completion":"2015-12","firstPosted":"2007-06-01","resultsPosted":"2011-03-15","lastUpdate":"2017-02-15"},"enrollment":547,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myeloid Leukemia, Chronic"],"interventions":[{"type":"DRUG","name":"Dasatinib","otherNames":["Sprycel®","BMS-354825"]},{"type":"DRUG","name":"Imatinib","otherNames":[]}],"arms":[{"label":"Dasatinib","type":"EXPERIMENTAL"},{"label":"Imatinib","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this clinical research study is to compare the confirmed complete cytogenetic response of dasatinib with that of imatinib within 12 months after randomization in patients with newly diagnosed chronic-phase Philadelphia positive chronic myeloid leukemia. The safety of this treatment will also be studied.","primaryOutcome":{"measure":"Number of Participants With Best Confirmed Complete Cytogenetic Response (cCCyR) Within 12 Months","timeFrame":"Pretreatment, every 3 months up to 12 months","effectByArm":[{"arm":"Dasatinib","deltaMin":204,"sd":null},{"arm":"Imatinib","deltaMin":177,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0056"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":109,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Chile","China","Colombia","Czechia","Denmark","France","Germany","Greece","Hungary","India","Italy","Japan","Mexico","Netherlands","Peru","Poland","Russia","Singapore","South Korea","Spain","Turkey (Türkiye)"]},"refs":{"pmids":["30120281","26118315","24357015","24311723","22160483","20525995"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":90,"n":258},"commonTop":["DIARRHOEA","NAUSEA","NEUTROPENIA","PYREXIA","THROMBOCYTOPENIA"]}}